omeprazole and Hemorrhage, Peptic Ulcer studies

Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.

Research Excerpts

Excerpt	Relevance	Reference
" ranitidine in 45 patients admitted as an emergency with an endoscopic diagnosis of bleeding duodenal ulcer."	10.18	[Intravenous omeprazole versus ranitidine in the treatment of hemorrhagic duodenal ulcer: a prospective randomized study]. ( Amadori, L; Arnone, F; Barillari, P; Bolognese, A; Cardi, M; Muttillo, IA; Sammartino, P; Signorelli, C, 1997)
"Clopidogrel causes significantly less symptomatic peptic ulcer disease and gastrointestinal bleeding than low-dose aspirin in average-risk patients."	9.11	Clopidogrel plus omeprazole compared with aspirin plus omeprazole for aspirin-induced symptomatic peptic ulcers/erosions with low to moderate bleeding/re-bleeding risk -- a single-blind, randomized controlled study. ( Chang, CM; Chen, WH; Ng, FH; Wong, BC; Wong, SY, 2004)
"After endoscopic treatment of bleeding peptic ulcers, a high-dose infusion of omeprazole substantially reduces the risk of recurrent bleeding."	9.09	Effect of intravenous omeprazole on recurrent bleeding after endoscopic treatment of bleeding peptic ulcers. ( Chan, AC; Chan, FK; Chung, SC; Lau, JY; Lee, CW; Lee, KK; Ng, EK; Sung, JJ; Wong, SK; Wu, JC; You, JH; Yung, MY, 2000)
"Parenteral omeprazole is better than parenteral ranitidine in keeping the intragastric pH above the proteolytic range for pepsin in patients with bleeding duodenal ulcers."	9.08	[Evaluation of intravenous ranitidine and omeprazole effect on the 24-hour gastric ph-metry in duodenal ulcer hemorrhage]. ( Artal, A; Barrao, ME; Blas, JM; Lanas, A; López, J; Moliner, FJ, 1996)
"A trial was carried out to compare the efficacy and safety of ranitidine 300 mg die, famotidine 40 mg die and omeprazole 20 mg die in short-term treatment of bleeding duodenal ulcer in 3 groups of 15 patients."	9.08	[Comparison between ranitidine, famotidine, and omeprazole in the treatment of bleeding duodenal ulcer]. ( Maculotti, L; Pradella, P, 1995)
"Thirty-five patients with duodenal ulcer bleeding and Helicobacter pylori-colonization were assigned to receive 2 x 20 mg omeprazole and 3 x 750 mg amoxycillin daily for 2 weeks."	9.08	Omeprazole-amoxycillin therapy for eradication of Helicobacter pylori in duodenal ulcer bleeding: preliminary results of a pilot study. ( Brennenstuhl, M; Hammar, CH; Jaspersen, D; Körner, T; Schorr, W, 1995)
"To evaluate the omeprazole maintenance therapy in patients with recurrent ulcer bleeding after surgery for duodenal ulcer."	7.73	Omeprazole maintenance therapy prevents recurrent ulcer bleeding after surgery for duodenal ulcer. ( Demertzis, K; Emmanuel, T; Ladas, SD; Polymeros, D; Tassios, P; Triantafyllou, K, 2006)
"We retrospectively investigated the efficacy of high dose omeprazole compared to a combined therapy of famotidine, pirenzepine and antacid for acute upper gastrointestinal hemorrhage (AUGIH) also adjuvant to endoscopic injection therapy if indicated."	7.69	[High-dose omeprazole versus famotidine, pirenzepine and antacid in therapy of acute upper gastrointestinal hemorrhage in a retrospective comparison]. ( Busam, J; Garbe, WE, 1994)
" ranitidine in 45 patients admitted as an emergency with an endoscopic diagnosis of bleeding duodenal ulcer."	6.18	[Intravenous omeprazole versus ranitidine in the treatment of hemorrhagic duodenal ulcer: a prospective randomized study]. ( Amadori, L; Arnone, F; Barillari, P; Bolognese, A; Cardi, M; Muttillo, IA; Sammartino, P; Signorelli, C, 1997)
"Treatment with omeprazole also failed to bring about healing of the ulceration which, at times, measured up to 10 cm in diameter."	5.28	Failure of ranitidine and omeprazole treatment in eosinophilic gastritis with ulceration. ( Gail, K; Mihaljevic, L; Stolte, M, 1991)
"Clopidogrel causes significantly less symptomatic peptic ulcer disease and gastrointestinal bleeding than low-dose aspirin in average-risk patients."	5.11	Clopidogrel plus omeprazole compared with aspirin plus omeprazole for aspirin-induced symptomatic peptic ulcers/erosions with low to moderate bleeding/re-bleeding risk -- a single-blind, randomized controlled study. ( Chang, CM; Chen, WH; Ng, FH; Wong, BC; Wong, SY, 2004)
"This analysis compared the efficacy of misoprostol, lansoprazole, and placebo in reducing the risk of gastric or duodenal ulcer recurrence in patients taking NSAIDs and low-dose aspirin."	5.11	Ulcer recurrence in high-risk patients receiving nonsteroidalanti-inflammatory drugs plus low-dose aspirin: results of a post HOC subanalysis. ( Amer, F; Christopoulos, NG; Goldstein, JL; Huang, B, 2004)
"Celecoxib was as effective as lansoprazole co-therapy in the prevention of recurrences of ulcer complications in subjects with a history of NSAID-related complicated peptic ulcers."	5.11	Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications. ( Chan, AO; Chu, KM; Hu, WH; Hui, WM; Lai, KC; Lam, SK; Wong, BC; Wong, J; Wong, WM, 2005)
"After endoscopic treatment of bleeding peptic ulcers, a high-dose infusion of omeprazole substantially reduces the risk of recurrent bleeding."	5.09	Effect of intravenous omeprazole on recurrent bleeding after endoscopic treatment of bleeding peptic ulcers. ( Chan, AC; Chan, FK; Chung, SC; Lau, JY; Lee, CW; Lee, KK; Ng, EK; Sung, JJ; Wong, SK; Wu, JC; You, JH; Yung, MY, 2000)
" In a prospective clinical trial, primed infusions of different dosages of omeprazole (8 or 4 mg/h) after a bolus (40 mg) produced consistently high intragastric pH values in patients with bleeding duodenal ulcer."	5.09	Effect of intragastric pH on control of peptic ulcer bleeding. ( Dai, S; Jia, L; Li, Y; Nie, Y; Sha, W; She, Q; Wu, H; Yu, W, 2000)
"Bleeding due to duodenal ulcer was not observed in any patients who received clarithromycin plus omeprazole, whereas five patients in the omeprazole treatment group and six patients in the ranitidine treatment group experienced an episode of ulcer-related hemorrhage during follow-up."	5.09	The effect of antibiotic therapy on bleeding from duodenal ulcer. ( Olson, CA; Sonnenberg, A; Zhang, J, 1999)
"5) with rheumatoid arthritis or osteoarthritis, requiring chronic intake of NSAIDs (at least 8 weeks prior to the start of the study), were randomised and enrolled to receive either 40 mg pantoprazole (n=70) or placebo (n=34) once daily, for 12 weeks."	5.09	Efficacy of pantoprazole in the prevention of peptic ulcers, induced by non-steroidal anti-inflammatory drugs: a prospective, placebo-controlled, double-blind, parallel-group study. ( Bianchi Porro, G; Imbesi, V; Lazzaroni, M; Montrone, F; Santagada, T, 2000)
"A trial was carried out to compare the efficacy and safety of ranitidine 300 mg die, famotidine 40 mg die and omeprazole 20 mg die in short-term treatment of bleeding duodenal ulcer in 3 groups of 15 patients."	5.08	[Comparison between ranitidine, famotidine, and omeprazole in the treatment of bleeding duodenal ulcer]. ( Maculotti, L; Pradella, P, 1995)
" pylori infection and duodenal ulcer bleeding were treated with omeprazole (40 mg/day for 4 wk), colloidal bismuth (480 mg/day for 2 wk), amoxicillin (2 g/day for 1 wk), and metronidazole (750 mg/day for 1 wk), and followed up for 48 months."	5.08	Eradication of Helicobacter pylori reduces the rate of duodenal ulcer rebleeding: a long-term follow-up study. ( Macri, G; Milani, S; Passaleva, MT; Salvadori, G; Surrenti, C; Surrenti, E, 1998)
"Parenteral omeprazole is better than parenteral ranitidine in keeping the intragastric pH above the proteolytic range for pepsin in patients with bleeding duodenal ulcers."	5.08	[Evaluation of intravenous ranitidine and omeprazole effect on the 24-hour gastric ph-metry in duodenal ulcer hemorrhage]. ( Artal, A; Barrao, ME; Blas, JM; Lanas, A; López, J; Moliner, FJ, 1996)
"In two parallel studies, 20 patients with bleeding duodenal ulcers and 20 patients with bleeding gastric ulcers were randomly assigned to receive either ranitidine (0."	5.08	Efficacy of primed infusions with high dose ranitidine and omeprazole to maintain high intragastric pH in patients with peptic ulcer bleeding: a prospective randomised controlled study. ( Blum, AL; Börsch, G; Labenz, J; Leusing, C; Peitz, U; Tillenburg, B, 1997)
"To evaluate whether eradication with omeprazole and amoxicillin results in a reduction of ulcer recurrence and rebleeding in patients with Helicobacter pylori-associated duodenal ulcer hemorrhage, patients with upper gastrointestinal hemorrhage from duodenal ulcers with stigmata of recent hemorrhage, a drop in hemoglobin level of more than 2 g/dL, and documented H."	5.08	Helicobacter pylori eradication reduces the rate of rebleeding in ulcer hemorrhage. ( Brennenstuhl, M; Hammar, CH; Jaspersen, D; Koerner, T; Raschka, C; Schorr, W, 1995)
"Thirty-five patients with duodenal ulcer bleeding and Helicobacter pylori-colonization were assigned to receive 2 x 20 mg omeprazole and 3 x 750 mg amoxycillin daily for 2 weeks."	5.08	Omeprazole-amoxycillin therapy for eradication of Helicobacter pylori in duodenal ulcer bleeding: preliminary results of a pilot study. ( Brennenstuhl, M; Hammar, CH; Jaspersen, D; Körner, T; Schorr, W, 1995)
" pylori-positive gastroduodenal ulcer bleeding, which could be commenced intravenously after endoscopic diagnosis, and to assess the effect of omeprazole pretreatment on bacterial eradication."	5.07	Intravenous omeprazole/amoxicillin and omeprazole pretreatment in Helicobacter pylori-positive acute peptide ulcer bleeding. A pilot study. ( Adamek, RJ; Freitag, M; Opferkuch, W; Rühl, GH; Wegener, M, 1994)
" The results of the randomized, double-blind, controlled trials show that misoprostol is the only antiulcer drug proven to be effective in the prevention of NSAID-induced gastric and duodenal ulcers as well as for reducing serious upper gastrointestinal complications (perforation and/or haemorrhage)."	4.79	Prevention of NSAID-gastropathy. ( Ardizzone, S; Bianchi Porro, G, 1996)
"The aim of this study is to assess the prevalence of peptic ulcer rebleeding by comparing patients who received omeprazole versus pantoprazole i."	3.76	[Prevalence of rebleeding from peptic ulcer in patients treated with proton pump inhibitors]. ( de Sousa, M; Garrido, A; Iborra, MI; Saperas, E, 2010)
"High-risk peptic ulcer bleeding patients received endoscopic therapy with epinephrine (adrenaline) injection plus intravenous omeprazole (40 mg bolus followed by 40 mg infusion every 12 h) for 3 days."	3.75	Efficacy of an intravenous proton pump inhibitor after endoscopic therapy with epinephrine injection for peptic ulcer bleeding in patients with uraemia: a case-control study. ( Cheng, YT; Fang, CT; Huang, CH; Liao, PC; Lin, HJ; Tseng, GC; Tseng, GY; Wang, PC; Yang, HB, 2009)
"In this retrospective study, high-dose omeprazole reduced the occurrence of rebleeding, need for surgery and mortality due to hemorrhagic shock in patients with high-risk peptic ulcer bleeding, as compared with standard-dose omeprazole."	3.74	Continuous infusion of high-dose omeprazole is more effective than standard-dose omeprazole in patients with high-risk peptic ulcer bleeding: a retrospective study. ( Bernard-Chabert, B; DI Martino, V; Massard, J; Poynard, T; Ratziu, V; Simon-Rudler, M; Thabut, D, 2007)
"To evaluate the omeprazole maintenance therapy in patients with recurrent ulcer bleeding after surgery for duodenal ulcer."	3.73	Omeprazole maintenance therapy prevents recurrent ulcer bleeding after surgery for duodenal ulcer. ( Demertzis, K; Emmanuel, T; Ladas, SD; Polymeros, D; Tassios, P; Triantafyllou, K, 2006)
"Ulcer-healing drugs should be continued after a 2-week course of omeprazole-containing anti-Helicobacter therapy for gastric ulcers and large peptic ulcers that have bled, but can be omitted in most patients with a bleeding duodenal ulcer."	3.70	Ulcer-healing drugs are required after eradication of Helicobacter pylori in patients with gastric ulcer but not duodenal ulcer haemorrhage. ( Hu, WH; Hui, WM; Lai, KC; Lam, SK; Wong, BC, 2000)
"We retrospectively investigated the efficacy of high dose omeprazole compared to a combined therapy of famotidine, pirenzepine and antacid for acute upper gastrointestinal hemorrhage (AUGIH) also adjuvant to endoscopic injection therapy if indicated."	3.69	[High-dose omeprazole versus famotidine, pirenzepine and antacid in therapy of acute upper gastrointestinal hemorrhage in a retrospective comparison]. ( Busam, J; Garbe, WE, 1994)
" The primary outcome measure of recurrent bleeding was compared between the two dosage regimens and between early and late endoscopy."	2.77	Effect of intravenous proton pump inhibitor regimens and timing of endoscopy on clinical outcomes of peptic ulcer bleeding. ( Ding, J; Fan, D; Gyawali, PC; Liu, L; Liu, N; Wu, K; Yang, Y; Yao, L; Zhang, D; Zhang, H, 2012)
"pantoprazole was 6."	2.74	Comparison of p.o. or i.v. proton pump inhibitors on 72-h intragastric pH in bleeding peptic ulcer. ( Gulzar, GM; Javid, G; Khan, BA; Khan, MA; Shah, AH; Sodhi, JS; U-Saif, R; Yatoo, GN; Zargar, SA, 2009)
"Outpatient management is safe for patients with non-variceal upper-GI bleeding who are at low risk of recurrent bleeding and death."	2.71	A randomized study of the safety of outpatient care for patients with bleeding peptic ulcer treated by endoscopic injection. ( Brullet, E; Cabrol, J; Calvet, X; Campo, R; Garcia-Monforte, N; Guell, M, 2004)
"Patients were evaluated for recurrence of bleeding for 1 month."	2.70	Recurrent bleeding from peptic ulcer associated with adherent clot: a randomized study comparing endoscopic treatment with medical therapy. ( Bleau, BL; Bracy, WP; Fleischer, DE; Gostout, CJ; Harford, WV; Keate, RF; Shaw, MJ; Sherman, KE, 2002)
"pylori is associated with low recurrence rates."	2.68	Eradication of Helicobacter pylori reduces the possibility of rebleeding in peptic ulcer disease. ( Giannikos, N; Karameris, A; Mavrogeorgis, A; Rallis, E; Rokkas, T, 1995)
"Cure of HP infection reduces the recurrence of peptic ulcer and of rebleeding from ulcer disease more effectively than does long-term maintenance therapy."	2.68	Antimicrobial therapy for Helicobacter pylori infection versus long-term maintenance antisecretion treatment in the prevention of recurrent hemorrhage from peptic ulcer: prospective nonrandomized trial on 125 patients. ( Cantero, J; Gómez-Cedenilla, A; Grávalos, RG; Pajares, JM; Santander, C, 1996)
", in the dosage used and in a selected group of patients with gastrointestinal bleeding, is similar."	2.67	[The treatment of upper digestive hemorrhage of peptic origin: intravenous ranitidine versus intravenous omeprazole]. ( Blasco Colmenarejo, MM; Cabot Lozano, A; Caneiro Alcubilla, E; García Molinero, MJ; García-Rayo Somoza, M; Herrero Quirós, C; Pérez Flores, R, 1994)
" If both Clopidogrel and PPI need to be prescribed, a split dosage regimen of PPI in the morning and clopidogrel in the evening can be recommended."	2.46	[Dilemma between gastroprotection and cardiovascular prevention]. ( Kandulski, A; Malfertheiner, P; Venerito, M, 2010)
"Omeprazole has been shown to provide more rapid symptom relief and to heal ulcers more quickly and reliably than H2-receptor antagonists in duodenal ulcer, gastric ulcer and reflux oesophagitis."	2.38	Clinical development programme for omeprazole. ( Walan, A, 1990)
" Common causes were discarded and the hypomagnesaemia was attributed to chronic use of the proton pump inhibitor, omeprazole."	1.40	From hypomagnesaemia to Zollinger-Ellison syndrome: an adverse effect of a proton pump inhibitor. ( Braun, E; Eyal, A; Naffaa, ME; Sueissa, A, 2014)
"A case of recurrent gastrointestinal hemorrhage in a child with systemic neurofibromatosis and primary ciliary dyskinesia (PCD) is presented."	1.35	Recurrent peptic ulcer disease in a pediatric patient with type 1 neurofibromatosis and primary ciliary dyskinesia. ( Di Stefano, V; Francavilla, R; Lionetti, E; Pavone, L; Principi, MB; Ruggieri, M, 2009)
"Especially patients with severe sepsis or septic shock are prone to develop lesions of the upper gastrointestinal tract with consecutive bleeding."	1.35	[Stress ulcer prophylaxis in septic patients. Evidence-based overview]. ( Elke, G; Schädler, D; Scholz, J; Weiler, N; Zick, G, 2008)
" Both indication and dosing regimen were appropriate in 21%."	1.33	Inappropriate use of intravenous pantoprazole: extent of the problem and successful solutions. ( Bates, D; Kaplan, GG; McDonald, D; Panaccione, R; Romagnuolo, J, 2005)
" A dosage of 0."	1.31	Omeprozole therapy in pediatric patients after liver and intestinal transplantation. ( Andersen, DA; Bergman, KL; Brown, CR; Davis, CK; Fox, IJ; Horslen, SP; Kaufman, SS; Langnas, AN; Lyden, ER; Olsen, KM; Shaw, BW; Sudan, DL, 2002)
" From these results we conclude that, following endoscopic hemostasis of bleeding ulcers, Omeprazol has no advantage over Ranitidin using our dosage regimes."	1.29	[Do proton pump inhibitors after endoscopic control of acute ulcer hemorrhage have an advantage over H2 receptor antagonists?]. ( Barnert, J; Fleischmann, R; Hendrich, H; Prassler, R; Richter, G; Wienbeck, M, 1995)
"Postoperative course was uneventful and recurrence of the ulcer was not observed."	1.29	[A case report of prosthetic valve replacement for malfunction of the Hancock valve in mitral position associated with recurrent peptic ulcer and renal dysfunction]. ( Aomi, S; Fujino, S; Hashimoto, A; Hirai, M; Koyanagi, H; Koyanagi, T; Sakahashi, H; Tokunaga, H, 1995)
"Treatment with omeprazole also failed to bring about healing of the ulceration which, at times, measured up to 10 cm in diameter."	1.28	Failure of ranitidine and omeprazole treatment in eosinophilic gastritis with ulceration. ( Gail, K; Mihaljevic, L; Stolte, M, 1991)

Timeframe	Studies, this research(%)	All Research%
pre-1990	1 (0.53)	18.7374
1990's	68 (36.17)	18.2507
2000's	94 (50.00)	29.6817
2010's	24 (12.77)	24.3611
2020's	1 (0.53)	2.80

Trial	Phase	Enrollment	Study Type	Start Date	Status
Effects of Different Omeprazole Dosing on Gastric pH in Non- Variceal Upper Gastrointestinal Bleeding: A Randomized Prospective Study[NCT03980496]	Phase 4	50 participants (Actual)	Interventional	2010-09-09	Completed
A Randomised, Double-blind, Parallel-group, Placebo Controlled Study of Esomeprazole i.v. (Bolus Infusion of 80 mg Followed by a Continuous Infusion of 8 mg Per Hour) Administered for 72 Hours to Assess Prevention of Rebleeding in Subjects That Have Under[NCT00251979]	Phase 3	1,312 participants (Actual)	Interventional	2005-10-31	Completed
Effects of Enteral Nutrition on Stress Ulcer Hemorrage. Multicenter Randomized Controlled[NCT03098537]		500 participants (Anticipated)	Interventional	2016-08-01	Recruiting
Intravenous Infusion of High Dose Omeprazole Versus Regular Dose Omeprazole on Recurrent Bleeding After Endoscopic Treatment of Bleeding Peptic Ulcers[NCT00519519]	Phase 3	126 participants (Actual)	Interventional	2004-07-31	Completed
Comparison of Intravenous Pantoprazole and Famotidine for Stress Ulcer Prophylaxis in Patients After Major Abdominal Surgery[NCT00839488]	Phase 4	6 participants (Actual)	Interventional	2008-04-30	Terminated (stopped due to the chief of GS left the hopsital and the successor did't want to keep on this study)
Comparison of High Dose Infusion and Low Dose Bolus Intravenous Omeprazole for Treatment of Bleeding Ulcer With Adherent Clot[NCT02536989]	Phase 4	40 participants (Actual)	Interventional	2009-03-31	Completed
Administration of Intravenous Proton Pump Inhibitor Prior to Endoscopy [APPE] in Patients With Upper Gastrointestinal Bleeding; a Double-Blind Placebo-Controlled Randomised Study.[NCT00164866]	Phase 4	638 participants	Interventional	2004-02-29	Completed
The Effect of Using Preendoscopic Proton Pump Inhibitors in Upper Gastrointestinal System Bleeding on Patient Prognosis[NCT05467358]		1,100 participants (Actual)	Observational	2021-07-01	Completed
Phase IV Study Comparing Helicobacter Pylori Empiric Eradication With Test-Guided Treatment in Patients With Peptic Ulcer Bleeding[NCT00687336]	Phase 4	178 participants (Anticipated)	Interventional	2008-03-31	Recruiting
Comparison of Esomeprazole and Famotidine for Stress Ulcer Prophylaxis in Neurosurgical Intensive Care Unit[NCT00633035]	Phase 4	60 participants (Actual)	Interventional	2007-09-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Intervention	Participants (Number)
Esomeprazole	29
Placebo	53

Intervention	Participants (Number)
Esomeprazole	27
Placebo	50

Intervention	Participants (Number)
Esomeprazole	22
Placebo	40

omeprazole and Hemorrhage, Peptic Ulcer

Research Excerpts

Research

Studies (188)

Authors

Clinical Trials (10)

Trial Overview

Trial Outcomes

Clinically Significant Rebleeding Within 30 Days

Clinically Significant Rebleeding Within 7 Days

Clinically Significant Rebleeding Within 72 Hours of Continous Infusion of Esomeprazole or Placebo

Death Related to Rebleeding Within 30 Days as Judged by the EpC

Death Within 30 Days

Death Within 72 Hours

Number of Blood Units Transfused Within 30 Days

Number of Blood Units Transfused Within 72 Hours

Number of Days Hospitalized Due to Rebleeding During the 30-day Treatment Period

Requirement for Endoscopic Re-treatment Within 30 Days

Requirement for Endoscopic Re-treatment Within 72 Hours

Requirement for Surgery Within 30 Days

Requirement for Surgery Within 72 Hours

Reviews

Trials

Other Studies

Authors	Studies
Zhang, J	2
Diao, P	1
Zhang, L	1
Labenz, J	3
Kubyshkin, VA	1
Petrov, DIu	1
Smirnov, AV	1
Rantanen, T	1
Udd, M	3
Honkanen, T	1
Miettinen, P	3
Kärjä, V	1
Rantanen, L	1
Julkunen, R	3
Mustonen, H	3
Paavonen, T	1
Oksala, N	1
Eyal, A	1
Sueissa, A	1
Braun, E	1
Naffaa, ME	1
Lenz, K	1
Buder, R	1
Firlinger, F	1
Lohr, G	1
Voglmayr, M	1
Chiu, PW	2
Joeng, HK	1
Choi, CL	1
Tsoi, KK	1
Kwong, KH	1
Lam, SH	1
Sung, JJ	8
Chwiesko, A	1
Charkiewicz, R	1
Niklinski, J	1
Luczaj, W	1
Skrzydlewska, E	1
Milewski, R	1
Baniukiewicz, A	1
Wroblewski, E	1
Rosolowski, M	1
Dabrowski, A	1
Lau, J	1
Lind, T	2
Persson, T	1
Eklund, S	1
Chan, FK	7
Evseev, MA	2
Ivakhov, GB	1
Golovin, RA	1
Tseng, GY	2
Fang, CT	1
Lin, HJ	7
Yang, HB	1
Tseng, GC	1
Wang, PC	1
Liao, PC	1
Cheng, YT	1
Huang, CH	1
Cheng, HC	2
Chang, WL	1
Yeh, YC	1
Chen, WY	1
Tsai, YC	1
Sheu, BS	2
Tsai, JJ	2
Hsu, YC	2
Perng, CL	4
Barkun, AN	1
Kuipers, EJ	2
Tan, VP	1
Wong, BC	5
Javid, G	4
Zargar, SA	3
U-Saif, R	1
Khan, BA	4
Yatoo, GN	2
Shah, AH	3
Gulzar, GM	4
Sodhi, JS	3
Khan, MA	2
Lionetti, E	1
Francavilla, R	1
Ruggieri, M	1
Di Stefano, V	1
Principi, MB	1
Pavone, L	1
Yih, V	1
Tejani, A	1
Piscoya, A	1
Lin, PC	1
Chang, CH	1
Hsu, PI	2
Tseng, PL	1
Huang, YB	1
Garrido, A	1
Iborra, MI	1
Saperas, E	1
de Sousa, M	1
Rahme, E	1
Bernatsky, S	1
Schaffer, AC	1
Grad, Y	1
Ross, JJ	1
Venerito, M	1
Kandulski, A	1
Malfertheiner, P	1
Grad, YH	1
Seifter, JL	1
Levy, BD	1
Loscalzo, J	1
den Hoed, CM	1
Sostres, C	1
Lanas, A	4
Chan, WH	1
Khin, LW	1
Chung, YF	1
Goh, YC	1
Ong, HS	1
Wong, WK	1
Keating, GM	1
Sakurada, T	1
Kawashima, J	1
Ariyama, S	1
Kani, K	1
Takabayashi, H	1
Ohno, S	1
Kato, S	1
Yakabi, K	1
Liu, N	1
Liu, L	1
Zhang, H	1
Gyawali, PC	1
Zhang, D	1
Yao, L	1
Yang, Y	1
Wu, K	1
Ding, J	1
Fan, D	1
Okamura, Y	1
Takeno, S	1
Takahashi, Y	1
Moroga, T	1
Yamashita, S	1
Kawahara, K	1
Kawakubo, K	1
Fujishima, M	1
Wu, XP	1
He, JR	1
Wang, CL	1
Ling, QH	1
Cherniakevich, SA	1
Babkova, IV	1
Mikhalev, AI	1
Yildizdas, D	1
Yapicioglu, H	1
Yilmaz, HL	1
Hung, LC	1
Suen, BY	2
Wu, JC	4
Lee, KC	1
Leung, VK	1
Hui, AJ	1
To, KF	1
Leung, WK	3
Wong, VW	2
Chung, SC	3
Graham, DY	2
Church, NI	1
Palmer, KR	1
Kaviani, MJ	1
Hashemi, MR	1
Kazemifar, AR	1
Roozitalab, S	1
Mostaghni, AA	1
Merat, S	1
Alizadeh-Naini, M	1
Yarmohammadi, H	1
Lee, KK	4
You, JH	3
Wong, IC	1
Kwong, SK	1
Lau, JY	4
Chan, TY	1
Lau, JT	1
Leung, WY	1
Chung, SS	1
Hiramoto, JS	1
Terdiman, JP	1
Norton, JA	1
Fedele, E	1
Nurmohamed, MT	1
Lems, WF	1
Tashiro, M	1
Yoshikawa, I	1
Kume, K	1
Narita, R	1
Sugihara, Y	1
Otsuki, M	1
Ho, JT	1
Yung, MY	2
Lau, WH	1
Lee, VW	2
Sung, JY	1
Liu, CC	1
Lee, CL	1
Chan, CC	1
Tu, TC	1
Liao, CC	1
Wu, CH	1
Chen, TK	1
Pais, SA	1
Yang, R	1
Romero-Gómez, M	1
Martínez-Delgado, C	1
Hergueta, P	1
Navarro, JM	1
Garrido-Serrano, A	1
Santos, O	1
Montojo, C	1
Ng, FH	1
Wong, SY	1
Chen, WH	1
Chang, CM	1
Bustamante Baléna, M	1
Ponce García, J	1
Yap, LM	1
Hagan, S	1
Craig, A	1
Hebbard, GG	1
Young, GP	1
Bampton, PA	1
Brullet, E	1
Campo, R	1
Calvet, X	1
Guell, M	1
Garcia-Monforte, N	1
Cabrol, J	1
Guda, NM	1
Noonan, M	1
Kreiner, MJ	1
Partington, S	1
Vakil, N	1
Martin, RA	1
Lo, GH	1
Lo, CC	1
Lin, CK	1
Chan, HH	1
Wu, CJ	1
Shie, CB	1
Tsai, PM	1
Wu, DC	1
Wang, WM	1
Lai, KH	1
Goldstein, JL	1
Huang, B	1
Amer, F	1
Christopoulos, NG	1
Enns, R	2
Cryer, B	1
Kamada, T	1
Hata, J	1
Kusunoki, H	1
Kido, S	1
Hamada, H	1
Aoki, R	1
Nishida, T	1
Komoto, K	1
Todo, H	1
Sumioka, M	1
Tanimoto, T	1
Sanuki, E	1
Sumii, K	1
Ogoshi, H	1
Hidaka, T	1
Dongmei, Q	1
Chayama, K	1
Haruma, K	1
Avgerinos, A	1
Sgouros, S	1
Viazis, N	1
Vlachogiannakos, J	1
Papaxoinis, K	1
Bergele, C	1
Sklavos, P	1
Raptis, SA	1
Kao, AW	1
Chuang, CH	1
Julapalli, VR	1
Gostishchev, VK	1
Horvat, D	1
Vcev, A	1
Soldo, I	1
Timarac, J	1
Dmitrović, B	1
Misević, T	1
Ivezić, Z	1
Kraljik, N	1
Zullo, A	1
Hassan, C	1
Morini, S	1
Solomon, LK	1
Vogiatzis, I	1
Craig, E	1
Campbell, FC	1
Glazunov, VK	1
Rumiantsev, GV	1
Buka, GIu	1
Brikman, AE	1
Sumishevskiĭ, EV	1
Kondrat'eva, AB	1
Lai, KC	3
Chu, KM	2
Hui, WM	3
Hu, WH	3
Wong, WM	2
Chan, AO	2
Wong, J	2
Lam, SK	3
Töyry, J	1
Vanninen, E	1
Andrews, CN	1
Levy, A	1
Fishman, M	1
Hahn, M	1
Atkinson, K	1
Kwan, P	1
Triadafilopoulos, G	1
Kaplan, GG	1
Bates, D	1
McDonald, D	1
Panaccione, R	1
Romagnuolo, J	1
Armstrong, D	1
Agustí-Escasany, A	1
Vallano-Ferraz, A	1
Demertzis, K	1
Polymeros, D	1
Emmanuel, T	1
Triantafyllou, K	1
Tassios, P	1
Ladas, SD	1
Lo, WC	3
Cheng, YC	1
Yattoo, GN	2
Mujeeb, SA	1
Shah, NA	1
Shafi, HM	1
Jensen, DM	1
Pace, SC	1
Soffer, E	1
Comer, GM	1
Yilmaz, S	1
Bayan, K	1
Tüzün, Y	1
Dursun, M	1
Canoruç, F	1
Netzer, P	2
Inauen, W	2
Levin, B	1
Sacks, R	1
Simon-Rudler, M	1
Massard, J	1
Bernard-Chabert, B	1
DI Martino, V	1
Ratziu, V	1
Poynard, T	1
Thabut, D	1
Cheung, FK	1
Siu, P	1
Ng, EK	3
Elphick, DA	1
Riley, SA	1
Tran, HA	1
Kang, E	1
Becker, D	1
Schaffalitzky de Muckadell, OB	2
Elke, G	1
Schädler, D	1
Zick, G	1
Scholz, J	1
Weiler, N	1
Coté, GA	1
Rice, JP	1
Bulsiewicz, W	1
Norvell, JP	1
Christensen, K	1
Bobb, A	1
Postelnick, M	1
Howden, CW	2
Hirai, M	1
Hashimoto, A	1
Aomi, S	1
Tokunaga, H	1
Koyanagi, T	1
Sakahashi, H	1
Fujino, S	1
Koyanagi, H	1
Prassler, R	1
Hendrich, H	1
Barnert, J	1
Richter, G	1
Fleischmann, R	1
Wienbeck, M	1
Villanueva, C	1
Balanzó, J	2
Torras, X	1
Sáinz, S	1
Soriano, G	1
González, D	1
Vilardell, F	2
Swain, P	1
Kohler, B	2
Rösch, W	1
Otani, Y	1
Kitajima, M	1
Sugiyama, M	1
Watanabe, Y	1
Aoki, T	1
Hackelsberger, A	1
Jaspersen, D	3
Körner, T	1
Schorr, W	2
Brennenstuhl, M	2
Hammar, CH	2
Maculotti, L	1
Pradella, P	1
Rokkas, T	1
Karameris, A	1
Mavrogeorgis, A	1
Rallis, E	1
Giannikos, N	1
Koerner, T	1
Raschka, C	1
Laine, L	1
Della Beffa, V	1
Carelli-Basile, A	1
Leli, R	1
Fontana, D	1
Gomollón, F	1
Bajador, E	1
Schneider, S	1
Hébuterne, X	1
Chichmanian, RM	1
Rampal, P	1
Adamek, RJ	2
Freitag, M	1
Opferkuch, W	1
Rühl, GH	1
Wegener, M	2
Kiilerich, S	1
Rannem, T	1
Elsborg, L	1
Goletti, O	1
Sidoti, F	1
Lippolis, PV	1
De Negri, F	1
Cavina, E	1
Ell, C	1
Pérez Flores, R	1
García Molinero, MJ	1
Herrero Quirós, C	1
Blasco Colmenarejo, MM	1
Caneiro Alcubilla, E	1
García-Rayo Somoza, M	1
Cabot Lozano, A	1
Börsch, G	2
Dubracić, D	1
Pulanić, R	1
Katicić, M	1
Car, D	1
Georgijević, A	1
Cvitanović, B	1
Busam, J	1
Garbe, WE	1
Naveau, S	1
Bour, B	1
Pariente, EA	1
Hamelin, B	1
Garcia, E	1
McCloy, R	1
Nair, R	1
González Carro, P	1
Toro, H	1
Grosso, C	1
Rossi, A	1
Gambitta, P	1
Bini, M	1
Zanasi, G	1
Pirone, Z	1
Arcidiacono, R	1
Artal, A	2
Blás, JM	2
Arroyo, MT	1
Lopez-Zaborras, J	1
Sáinz, R	1
Chua, RT	1
Wang, K	1
Lee, CH	1
Lee, SD	2
Barrao, ME	1
Moliner, FJ	1
López, J	1
Santander, C	1
Grávalos, RG	1
Gómez-Cedenilla, A	1
Cantero, J	1
Pajares, JM	1
Vreeburg, EM	2
de Bruijne, HW	1
Snel, P	2
Bartelsman, JW	1
Rauws, EA	1
Tytgat, GN	1
Ardizzone, S	1
Bianchi Porro, G	2
Kung, NN	1
Yuen, NW	1
Ng, PW	1
Wong, KC	1
Chung, EC	1
Lim, BH	1
Choi, CH	1
Li, TH	1
Ma, HC	1
Kwok, SP	1
Khuroo, MS	1
Shah, AA	1
Sodi, JS	1
Saltzman, JR	1
Zawacki, JK	1
Gisbert, JP	1
Boixeda, D	1
Martín de Argila, C	1
Havelund, T	1
Harling, H	1
Boesby, S	1
Eriksson, S	2
Fernström, P	2
Hasselgren, G	3
Lundell, L	1
Aadland, E	1
Efskind, P	1
Falk, A	1
Hyltander, A	1
Söderlund, C	1
Berstad, A	1
Peitz, U	1
Leusing, C	1
Tillenburg, B	1
Blum, AL	1
Levy, MJ	1
Seelig, CB	1
Robinson, NJ	1
Ranney, JE	1
Munkel, L	1
French, L	1
Cardi, M	1
Muttillo, IA	1
Amadori, L	1
Barillari, P	1
Sammartino, P	1
Arnone, F	1
Signorelli, C	1
Bolognese, A	1
Riemann, JF	1
Schilling, D	1
Schauwecker, P	1
Wehlen, G	1
Dorlars, D	1
Maier, M	1
Senderovitz, T	1
Lasky, MR	1
Metzler, MH	1
Phillips, JO	1
Lee, FY	1
Chang, FY	1
Felder, LR	1
Barkin, JS	2
Macri, G	1
Milani, S	1
Surrenti, E	1
Passaleva, MT	1
Salvadori, G	1
Surrenti, C	1
Coraggio, F	1
Rotondano, G	1
Marmo, R	1
Balzanelli, MG	1
Catalano, A	1
Clemente, F	1
Moccia, F	1
Parola, PC	1
Keelan, M	1
Kirdeikis, P	1
Lee, J	1
Röhss, K	1
Sinclair, P	1
Thomson, AB	1
Suen, R	1
Lee, YT	1
Chan, HL	1
Lai, AC	1
Grimaz, S	1
Damiani, D	1
Brosolo, P	1
Skert, C	1
Geromin, A	1
de Pretis, G	1
Sonnenberg, A	1
Olson, CA	1
Eloubeidi, M	1
Rockey, DC	1
Bustamante, M	1
Stollman, N	1
Sugimoto, M	1
Kajimura, M	1
Hanai, H	1
Kaneko, E	1
Li, Y	1
Sha, W	1
Nie, Y	1
Wu, H	1
She, Q	1
Dai, S	1
Jia, L	1
Yu, W	1
Wong, SK	1
Lee, CW	1
Chan, AC	1
Libby, ED	1
Lazzaroni, M	1
Imbesi, V	1
Montrone, F	1
Santagada, T	1
Scheurlen, M	1
Bohle, W	1
Zoller, WG	1
Nehme, O	1
Savides, TJ	1
Pratha, V	1
Masoodi, I	1
Sharma, VK	1
Sahai, AV	1
Corder, FA	1
Palmu, A	1
Heikkinen, M	1
Janatuinen, E	1
Pasanen, P	1
Tarvainen, R	1
Kairaluoma, MV	1
Lohman, M	1
Fasseas, P	1
Leybishkis, B	1
Rocca, G	1
Zed, PJ	1
Loewen, PS	1
Slavik, RS	1
Marra, CA	1
Sánchez-Bueno, F	1
Marín, P	1
Ríos, A	1
Aguayo, JL	1
Robles, R	1
Piñero, A	1
Fernández, JA	1
Parrilla, P	1
Rollhauser, C	1
Fleischer, DE	2
Kaufman, SS	1
Lyden, ER	1
Brown, CR	1
Davis, CK	1
Andersen, DA	1
Olsen, KM	1
Bergman, KL	1
Horslen, SP	1
Sudan, DL	1
Fox, IJ	1
Shaw, BW	1
Langnas, AN	1
Bleau, BL	1
Gostout, CJ	1
Sherman, KE	1
Shaw, MJ	1
Harford, WV	1
Keate, RF	1
Bracy, WP	1
Lau, GK	1
Yuen, MF	1
Lai, CL	1
Mönkemüller, KE	1
Eloubeidi, MA	1
Heldwein, W	1
Schreiner, J	1
Müller-Lissner, S	1
Martí-Massó, JF	1
López de Munain, A	1
López de Dicastillo, G	1
Stolte, M	1
Gail, K	1
Mihaljevic, L	1
O'Leary, MJ	1
Park, GR	1
Langman, MJ	1
Walan, A	1
Brunner, G	1
Chang, J	1
Bank, S	1

Article	Year
[Endoscopic hemostasis in the treatment of the gastroduodenal ulcer bleeding]. Khirurgiia, 2013, Issue:9 Topics: Administration, Intravenous; Comparative Effectiveness Research; Duodenal Ulcer; Hemostasis, Endosco	2013
The efficacy and safety of proton pump inhibitors vs histamine-2 receptor antagonists for stress ulcer bleeding prophylaxis among critical care patients: a meta-analysis. Critical care medicine, 2010, Volume: 38, Issue:4 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Cimetidine; Critical Care; Histamine H2 Antagonists; Humans	2010
[Dilemma between gastroprotection and cardiovascular prevention]. Deutsche medizinische Wochenschrift (1946), 2010, Volume: 135, Issue:44 Topics: Alleles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases;	2010
Intravenous esomeprazole: a pharmacoeconomic profile of its use in the prevention of recurrent peptic ulcer bleeding. PharmacoEconomics, 2011, Volume: 29, Issue:6 Topics: Anti-Ulcer Agents; Esomeprazole; Humans; Injections, Intravenous; Omeprazole; Peptic Ulcer Hemorrhag	2011
[Management of gastrointestinal mucosal damage in patients with cerebrovascular disease]. Nihon rinsho. Japanese journal of clinical medicine, 2002, Volume: 60, Issue:8 Topics: Animals; Anti-Ulcer Agents; Cerebrovascular Disorders; Hemostasis, Endoscopic; Histamine H2 Antagoni	2002
Ulcers and nonvariceal bleeding. Endoscopy, 2003, Volume: 35, Issue:1 Topics: Anti-Ulcer Agents; Endoscopy, Gastrointestinal; Epinephrine; Hemostatic Techniques; Humans; Laser Co	2003
Evidence-based analysis: postoperative gastric bleeding: etiology and prevention. Surgical oncology, 2003, Volume: 12, Issue:1 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Cost-Benefit Analysis; D	2003
Diagnostic and therapeutic options in the management of nonvariceal upper gastrointestinal bleeding. Current gastroenterology reports, 2003, Volume: 5, Issue:6 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Diathermy; Endoscopy, Ga	2003
[Antisecretor treatment of digestive hemorrhage associated to peptic ulcer: an approximation to the available evidence]. Revista clinica espanola, 2004, Volume: 204, Issue:3 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Clinical Trials as Topic	2004
Proton pump inhibitors for acute upper GI bleeding. Drug and therapeutics bulletin, 2004, Volume: 42, Issue:6 Topics: Acute Disease; Aged; Anti-Ulcer Agents; Gastrointestinal Hemorrhage; Humans; Middle Aged; Omeprazole	2004
Appropriate use of intravenous proton pump inhibitors in the management of bleeding peptic ulcer. Digestive diseases and sciences, 2005, Volume: 50, Issue:7 Topics: Administration, Oral; Endoscopy; Enzyme Inhibitors; Gastric Mucosa; Hemostasis; Histamine H2 Antagon	2005
Review article: the role of antisecretory therapy in the management of non-variceal upper gastrointestinal bleeding. Alimentary pharmacology & therapeutics, 2005, Volume: 22 Suppl 3 Topics: Administration, Oral; Endoscopy, Gastrointestinal; Enzyme Inhibitors; Gastrointestinal Hemorrhage; H	2005
Intravenous proton pump inhibitor therapy: a rationale for use. Reviews in gastroenterological disorders, 2005, Volume: 5 Suppl 2 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Gastroesophageal Reflux;	2005
What should be done when initial endoscopic therapy for bleeding peptic ulcer fails? Endoscopy, 1995, Volume: 27, Issue:4 Topics: Animals; Anti-Ulcer Agents; Clinical Trials as Topic; Duodenal Ulcer; Hemostasis, Endoscopic; Humans	1995
[Therapy of ulcer hemorrhage: myths and reality]. Bildgebung = Imaging, 1994, Volume: 61 Suppl 1 Topics: Electrocoagulation; Endoscopy, Gastrointestinal; Fibrin Tissue Adhesive; Humans; Omeprazole; Peptic	1994
Surgery for acid suppression in the 1990s. Bailliere's clinical gastroenterology, 1993, Volume: 7, Issue:1 Topics: Anti-Ulcer Agents; Female; Gastric Acid; Gastric Mucosa; Helicobacter pylori; Humans; Intestinal Muc	1993
Helicobacter pylori eradication: the best long-term prophylaxis for ulcer bleeding recurrence? Endoscopy, 1995, Volume: 27, Issue:8 Topics: Anti-Ulcer Agents; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans;	1995
Prevention of NSAID-gastropathy. The Italian journal of gastroenterology, 1996, Volume: 28 Suppl 4 Topics: Adult; Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Duodenal Ulcer	1996
[What is the current therapeutic role of omeprazole in gastroduodenal ulcer disease?]. Revista espanola de enfermedades digestivas, 1997, Volume: 89, Issue:2 Topics: Anti-Ulcer Agents; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans;	1997
[Intravenous omeprazole versus ranitidine in the treatment of hemorrhagic duodenal ulcer: a prospective randomized study]. Annales de chirurgie, 1997, Volume: 51, Issue:2 Topics: Aged; Aged, 80 and over; Anti-Ulcer Agents; Duodenal Ulcer; Female; Humans; Injections, Intravenous;	1997
The efficacy of proton-pump inhibitors in acute ulcer bleeding: a qualitative review. Journal of clinical gastroenterology, 2000, Volume: 30, Issue:1 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Duodenal Ulcer; Humans;	2000
[Proton pump inhibitors in acute ulcer bleeding--what is evident?]. Deutsche medizinische Wochenschrift (1946), 2000, Dec-22, Volume: 125, Issue:51-52 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Endoscopy, Gastrointesti	2000
Helicobacter pylori eradication is superior to ulcer healing with or without maintenance therapy to prevent further ulcer haemorrhage. Alimentary pharmacology & therapeutics, 2001, Volume: 15, Issue:12 Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infection	2001
Meta-analysis of proton pump inhibitors in treatment of bleeding peptic ulcers. The Annals of pharmacotherapy, 2001, Volume: 35, Issue:12 Topics: Adult; Anti-Ulcer Agents; Humans; Omeprazole; Peptic Ulcer Hemorrhage; Proton Pump Inhibitors; Rando	2001
Nonvariceal upper gastrointestinal bleeding. Endoscopy, 2002, Volume: 34, Issue:2 Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Endoscopy, Gastrointestinal; Gastrointes	2002
Clinical development programme for omeprazole. Digestion, 1990, Volume: 47 Suppl 1 Topics: Drug Administration Schedule; Esophagitis, Peptic; Humans; Omeprazole; Peptic Ulcer; Peptic Ulcer He	1990

Intervention	blood units (Number)
Esomeprazole	589
Placebo	935

Intervention	blood units (Number)
Esomeprazole	492
Placebo	738